TC-99M (TC-99M) MERCAPTOACETYLTRIGLYCINE - UPDATE ON THE NEW TC-99M RENAL TUBULAR FUNCTION AGENT

被引:113
作者
ESHIMA, D
TAYLOR, A
机构
[1] EMORY UNIV,DEPT RADIOL,ATLANTA,GA 30322
[2] UNIV NEW MEXICO,COLL PHARM,ALBUQUERQUE,NM 87131
关键词
D O I
10.1016/S0001-2998(05)80082-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Technetium-99m (99mTc) mercaptoacetyltriglycine (MAG3) is a new renal radiopharmaceutical that was recently introduced as a 99mTc-labeled replacement for iodine-131 (131I) o-iodohippurate (OIH). Since its introduction, a wide variety of in vitro and in vivo studies have been performed to characterize the high-performance liquid chromatography (HPLC)-purified complex and kit formulations. [99mTc]MAG3 has a slower plasma clearance, a higher plasma protein binding, less red blood cell (RBC) penetration, a lower extraction ratio, and a smaller volume of distribution than OIH. Because of the slower plasma clearance, [99mTc] MAG3 cannot be used as a direct measurement of effective renal plasma flow. Simplified methods have been developed to calculate [99mTc]MAG3 clearances, as well as regression equations to convert these clearances to an equivalent OIH value. The image quality of [99mTc]MAG3 is superior to [131I]OIH; the renogram curves and the fraction of the dose of the two agents that appears in the urine are almost identical, even though the plasma clearance of [99mTc-]MAG3 is only 50% to 65% that of OIH. [99mTc]MAG3 compares favorably with OIH in patients with a wide range of clinical problems. The radiation dose to a patient with normal renal function using standard imaging doses is higher for [99mTc]MAG3 than for [131I]OIH, but in patients with impaired renal function, the radiation dose from [131I]OIH is much higher than [99mTc]MAG3. [99mTc]MAG3 also provides superior image quality compared with [99mTc]diethylenetriaminepentaacetic acid (DTPA) in patients with impaired renal function, but it is important to note that [99mTc]MaG3 cannot be used to mesure the glomerular filtration rate (GFR). [99mTc]MAG3 is the most promising [su99m]Tc tubular function agent to date, and it has replaced OIH and [99mTc]DTPA in a number of institutions. However, therefore, they should not be expected to behave identically in all clinical conditions. © 1991 W.B. Saunders Company. All rights reserved.
引用
收藏
页码:61 / 73
页数:13
相关论文
共 83 条
[1]   CLINICAL-EXPERIENCE WITH TC-99M-MAG3, MERCAPTOACETYLTRIGLYCINE, AND A COMPARISON WITH TC-99M-DTPA [J].
ALNAHHAS, AA ;
JAFRI, RA ;
BRITTON, KE ;
SOLANKI, K ;
BOMANJI, J ;
MATHER, S ;
CARROLL, MA ;
ALJANABI, M ;
FRUSCIANTE, V ;
AJDINOWIC, B ;
FIORE, F ;
DEMENA, S ;
NIMMON, CC .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1988, 14 (9-10) :453-462
[2]  
BANNISTER KM, 1990, J NUCL MED, V31, P1568
[3]   A NEW RADIOPHARMACEUTICAL FOR GAMMA-CAMERA RENOGRAPHY [J].
BEVIS, CRA ;
LAWSON, RS ;
SHIELDS, RA ;
TESTA, HJ .
NUCLEAR MEDICINE COMMUNICATIONS, 1983, 4 (06) :386-394
[4]  
BHAGARVA KK, 1988, J LABEL COMP RADIOPH, V25, P943
[5]  
BORMANS G, 1990, European Journal of Nuclear Medicine, V16, P538
[6]  
BRANDAU W, 1990, CONTRIB NEPHROL, V79, P11
[7]  
BRANDAU W, 1988, APPL RADIAT ISOTOPES, V39, P121
[8]  
BRANDAU W, 1989, TRENDS POSSIBILITIES, P409
[9]  
BRITTON KE, 1990, CONTRIB NEPHROL, V79, P28
[10]  
BRITTON KE, 1989, J NUCL MED, V30